Applied Therapeutics announced it is again delaying plans to seek U.S. FDA approval of its AT-007 drug candidate for the genetic disorder galactosemia. The decision…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.